Last Updated : January 8, 2025
Details
Generic Name:
venetoclax
Project Status:
Pending
Therapeutic Area:
Mantle cell lymphoma (MCL)
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Venclexta
Project Line:
Reimbursement Review
Project Number:
PC0402-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Venclexta in combination with ibrutinib, is indicated for the treatment of adult patients with MCL who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Venclexta, in combination with ibrutinib, is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 8, 2025